<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04861558</url>
  </required_header>
  <id_info>
    <org_study_id>EFFIPEC01</org_study_id>
    <nct_id>NCT04861558</nct_id>
  </id_info>
  <brief_title>Efficacy of Hyperthermic Intraperitoneal Chemotherapy</brief_title>
  <acronym>EFFIPEC</acronym>
  <official_title>EFFIPEC - Efficacy of Hyperthermic Intraperitoneal Chemotherapy, Single-arm Phase I Study, Followed by an Open-label, Randomized, Controlled Registry-based Phase III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Uppsala University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A dose titration study and a combined superiority registry-based open-label randomized&#xD;
      control trial is planned to answer the trial objectives. The study will be registry-based to&#xD;
      allow simpler and more comprehensive follow-up. Patients with colorectal cancer will be&#xD;
      treated with cytoreductive surgery (CRS) together with either standard oxaliplatin HIPEC (the&#xD;
      control for the efficacy study) or oxaliplatin/irinotecan HIPEC in combination with 5-FU&#xD;
      24-hour EPIC. The 5-FU will be administered postoperatively when the abdomen is completely&#xD;
      sutured. The drug is divided equally into 2 injections of 200 ml each and injected through&#xD;
      two abdominal drains that are clamped for 16 hours.&#xD;
&#xD;
      For dose escalation, the titration groups (á 3 or 6 patients) are followed for 30 days&#xD;
      postoperatively after which the Data Monitoring Committee (DMC) will determine whether or not&#xD;
      to increase the 5-FU dose for the following group of patients.&#xD;
&#xD;
      To study efficacy, randomization is performed intraoperatively. The patient is followed up&#xD;
      postoperatively for a total of 3 years for the secondary endpoints which may be extended by&#xD;
      the study committee to 5 years. Since the trial is registry based, the long-term follow-up&#xD;
      does not require separate eCRF evaluations. These evaluations can be automatically retrieved&#xD;
      from the registry - both recurrence data, quality of life, and morbidity data. Some specific&#xD;
      eCRF evaluations will be integrated as a separate study part of the HIPEC registry, such as&#xD;
      inclusion/exclusion criteria and adverse event reporting (including SUSAR reporting).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">December 2029</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence-free survival</measure>
    <time_frame>12 months after treatment</time_frame>
    <description>To study the recurrence-free survival (RFS) of patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years after treatment</time_frame>
    <description>Survival is followed through the HIPEC registry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free survival</measure>
    <time_frame>5 years after treatment</time_frame>
    <description>Survival is followed through the HIPEC registry. The RECIST criteria are used to determine recurrence and site of first recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complication rate</measure>
    <time_frame>Within 30 days after treatment</time_frame>
    <description>Morbidity is registered in the HIPEC registry within 30 days of treatment administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient evaluations of quality of life</measure>
    <time_frame>3 years after treatment</time_frame>
    <description>EORTC QLQ questionnaire filled out at baseline, 12 and 36 months after surgery using the established QoL database.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">356</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Peritoneal Metastases</condition>
  <arm_group>
    <arm_group_label>Standard HIPEC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injection of oxaliplatin 460 mg/m2 and an intraoperational IV of 5-fluorouracil 400 mg/m2, and calcium folinate 60 mg/m2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intensified HIPEC+EPIC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of irinotecan 360 mg/m2 and 5-fluorouracil 24-hr EPIC 250-850 mg/m2 in combination with Oxaliplatin 360 mg/m2 and an intraoperational IV of 5-fluorouracil bolus 400 mg/m2 with calcium folinate 60mg/m2.&#xD;
The EPIC treatment is given after the abdomen is completely sutured in the operating theater. The dose will be divided equally into 2 injections á 200ml each through two abdominal drains.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5Fluorouracil</intervention_name>
    <description>Injection of 250-850 mg/m2.</description>
    <arm_group_label>Intensified HIPEC+EPIC</arm_group_label>
    <other_name>Fluorouracil Accord</other_name>
    <other_name>Fluorouracil Tevo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Injection of 360 mg/m2</description>
    <arm_group_label>Intensified HIPEC+EPIC</arm_group_label>
    <other_name>Irinotecan Accord</other_name>
    <other_name>Irinotecan Actavis</other_name>
    <other_name>Irinotecan Fresenius Kabi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Injection of 460 mg/m2</description>
    <arm_group_label>Standard HIPEC</arm_group_label>
    <other_name>Oxaliplatin Accord</other_name>
    <other_name>Oxaliplatin Teva</other_name>
    <other_name>Oxaliplatin Fresenius Kabi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of written informed consent prior to any study specific procedures.&#xD;
&#xD;
          -  ECOG Performance Status Score 0,1 or 2&#xD;
&#xD;
          -  Adequate kidney, liver, bone marrow function according to laboratory tests&#xD;
&#xD;
          -  For females of childbearing potential, a negative pregnancy test must be documented&#xD;
&#xD;
          -  ≥ 18 years old and &lt;75 years old&#xD;
&#xD;
          -  Colorectal cancer with peritoneal metastases&#xD;
&#xD;
          -  All patients deemed eligible for CRS and HIPEC according to clinical routine&#xD;
             management during a HIPEC multidisciplinary board at each respective hospital can be&#xD;
             included.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous severe toxicity/allergic reactions to systemic chemotherapy agents&#xD;
             oxaliplatin or irinotecan or 5-fluorouracil&#xD;
&#xD;
          -  Unable to tolerate intensified HIPEC treatment due to comorbidity&#xD;
&#xD;
          -  Metastasis other than peritoneum&#xD;
&#xD;
          -  Pregnant or lactating (nursing) women&#xD;
&#xD;
          -  Active infections requiring antibiotics&#xD;
&#xD;
          -  Active liver disease with positive serology for active hepatitis B, C, or known HIV&#xD;
&#xD;
          -  Concurrent administration of any cancer therapy other than planned study treatment&#xD;
             within 4 weeks prior to and up to 4 weeks after study treatment&#xD;
&#xD;
          -  Incomplete cytoreduction defined as completeness of cytoreduction score 1-3&#xD;
&#xD;
          -  Histopathology of other origin than colorectal cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Cashin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uppsala University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Cashin, MD, PhD</last_name>
    <phone>+46 (0)18 6174304</phone>
    <email>peter.cashin@surgsci.uu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lana Ghanipour, MD, PhD</last_name>
    <phone>+46 (0)18 6110000</phone>
    <email>lana.ghanipour@surgsci.uu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sahlgrenska östra sjukhuset</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elinor Bexe-Lindskog, MD,PhD</last_name>
      <email>elinor.bexe_lindskog@vgregion.se</email>
    </contact>
    <investigator>
      <last_name>Elinor ö Bexe-Lindskog, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skånes universitetssjukhus</name>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingvar Syk, MD, PhD</last_name>
      <email>ingvar_syk@telia.com</email>
    </contact>
    <investigator>
      <last_name>Ingvar Syk, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska sjukhuset</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriella Jansson Palmer</last_name>
      <email>gabriella.jansson-palmer@sll.se</email>
    </contact>
    <investigator>
      <last_name>Gabriella Jansson Palmer, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Akademiska sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lana Ghanipour</last_name>
      <email>lana.ghanipour@akademiska.se</email>
    </contact>
    <investigator>
      <last_name>Lana Ghanipour, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 6, 2021</study_first_submitted>
  <study_first_submitted_qc>April 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperthermia</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Completely anonymized IPD will be shared. All dates, HIPEC center treatment, referral city, and personal identification will be removed.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>To be shared at the time of phase 3 trial publication. Available for 10 years.</ipd_time_frame>
    <ipd_access_criteria>Access by request only from the corresponding author. Study protocol, SAP, ICF will be publicly available without request.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

